Studying the apparently paradoxical ability of the MYCN protoncogene to induce apoptosis or the apoptosis-sensitive phenotype in neuroblastoma cells provided important clues on the activity of MDM2/p53 antagonists and on their potential pharmacological use in NB therapy. Here, MDM2 is linked to neuroblastoma.